Therapeutic synergy of Triptolide and MDM2 inhibitor against acute myeloid leukemia through modulation of p53-dependent and -independent pathways

Dysregulation of MDM2, a p53 negative regulator, frequently occurs in acute myeloid leukemia (AML) and is associated with unfavorable prognoses, rendering the p53-MDM2 axis an attractive target for the development of small-molecule inhibitors. MDM2 antagonists have been intensely developed but only...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Qinwei, Deng, Suqi, Deng, Manman, Shi, Yuanfei, Zhong, Mengya, Ding, Lihong, Jiang, Yuelong, Zhou, Yong, Carter, Bing Z., Xu, Bing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013083/
https://www.ncbi.nlm.nih.gov/pubmed/35429966
http://dx.doi.org/10.1186/s40164-022-00276-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013083/
https://www.ncbi.nlm.nih.gov/pubmed/35429966
http://dx.doi.org/10.1186/s40164-022-00276-z

Ejemplares similares